SGLT2 inhibitors (SGLT2is) are prescribed for glomerular diseases in combination with renin-angiotensin system (RAS) blockade to enhance proteinuria reduction in patients who have not achieved complete remission with RAS blockade alone. Here, SLC5A2 is linked to glomerular disorder.